Fundraising Fox
Amaroq Therapeutics
6 employees on LinkedIn · 4 known investors
Find your way into Amaroq Therapeutics
Sign up to find every way you can get introduced to Amaroq Therapeutics
- Your email: who you already know at Amaroq Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Amaroq Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Amaroq Therapeutics develops first-in-class therapies targeting long non-coding RNAs (lncRNAs) implicated in oncology and other diseases. The company uses proprietary platforms to discover, validate, and create precision medicines against disease-relevant lncRNAs, focusing initially on oncology programs with high unmet medical need.
Investors · 4
Booster Innovation Fundlisted by Booster Innovation FundWellington
How we know: Booster Innovation Fund's portfolio page · Not right? Tell us
Cure Kids Ventureslisted by Cure Kids VenturesAuckland
How we know: Cure Kids Ventures's portfolio page · funding news · Not right? Tell us
Brandon Capital PartnersreportedMelbourne
How we know: funding news · Not right? Tell us
Frequently asked questions
- What does Amaroq Therapeutics do?
- Amaroq Therapeutics develops first-in-class therapies targeting long non-coding RNAs (lncRNAs) implicated in oncology and other diseases. The company uses proprietary platforms to discover, validate, and create precision medicines against disease-relevant lncRNAs, focusing initially on oncology programs with high unmet medical need.
- Who are Amaroq Therapeutics's investors?
- Amaroq Therapeutics's investors include Booster Innovation Fund, Cure Kids Ventures, Tenmile, Brandon Capital Partners.